Original Investigation

Absolute Risk of Progression to Cognitive Impairment Based on Plasma Phosphorylated Tau 217, Age, Sex, and APOE ε4

JAMA Neurology 10.1001/jamaneurol.2026.4292

November 16, 2026 at 11:00 AM EST

Read the full article

Are plasma phosphorylated tau 217 (p-tau217) concentrations associated with 5- and 10-year absolute risk of developing mild cognitive impairment and dementia in cognitively unimpaired individuals? This cohort study found that higher baseline values for p-tau217 and p-tau217/amyloid β 42 were associated with increased risk of developing cognitive impairment at 5 and 10 years. After accounting for p-tau217, APOE ε4 status had only a modest association, while baseline age had a strong association with absolute risk. In cognitively unimpaired adults, plasma p-tau217 concentrations may help predict an individual’s 5- and 10-year absolute risk of developing cognitive impairment, supporting prognosis, individualized counseling, and improved participant selection for Alzheimer disease prevention trials.

Corresponding Author: Alicia Algeciras-Schimnich, PhD, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (algeciras.alicia@mayo.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2026.4292

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks